Fundraising Fox
Renbioscience
1 employees on LinkedIn · 1 known investors
Find your way into Renbioscience
Sign up to see every warm intro you have to Renbioscience
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Renbioscience team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Ren BioScience develops small-molecule therapies aimed at preserving organ function, including an oral lead compound for inherited retinal diseases and preclinical programs targeting acute kidney injury and mitochondrial-driven metabolic and autoimmune conditions. Its focus is on protecting cells from irreversible injury across ophthalmic, renal, and metabolic disease areas.
Founders & leadership
RS
Ray StevensChief Executive OfficerRay Stevens is Chief Executive Officer of Ren BioScience, which develops small-molecule therapies for inherited retinal diseases, acute kidney injury, and mitochondrial-driven conditions. He has held leadership roles at GSK and multiple venture-backed biotechnology companies, with experience spanning drug discovery through regulatory readiness and also advises biotech CEOs and boards on development strategy.
DB
Dale BennyhoffChief Operating OfficerDale Bennyhoff is Chief Operating Officer at Ren BioScience. He brings expertise in CMC, quality, and regulatory strategy across drug development, with a track record of supporting IND clearances and regulatory submissions for early- and mid-stage biotech programs.
DS
Dr. Stewart McCallumChief Medical Officer
Investors · 1
Related companies · 3
Dren BioDren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
RenBioRenBio develops DNA-based therapeutic technology that uses intramuscular injection of therapeutic-encoding "bioblueprints" so a patient's own muscle cells produce antibodies and therapeutic proteins to prevent and treat diseases, including infectious diseases. The company works in the antibody and therapeutic protein field, aiming to overcome obstacles in delivery, durability, and cost.
NeoGenomicsNeoGenomics develops diagnostic tests and tools for cancer care, including tests for immunotherapy response monitoring, therapy selection, and minimal residual disease detection.
Companies working in the same space as Renbioscience.
Frequently asked questions
- What does Renbioscience do?
- Ren BioScience develops small-molecule therapies aimed at preserving organ function, including an oral lead compound for inherited retinal diseases and preclinical programs targeting acute kidney injury and mitochondrial-driven metabolic and autoimmune conditions. Its focus is on protecting cells from irreversible injury across ophthalmic, renal, and metabolic disease areas.
- Who are Renbioscience's investors?
- Renbioscience's investors include The Innovation Space.